Management of pancytopenia blood component transfusion and recombinant growth factor
Watanabe, K.; Yonekura, S.; Komatsuda, M.; Yabe, M.
Nihon Rinsho. Japanese Journal of Clinical Medicine 48(9): 2035-2040
1990
ISSN/ISBN: 0047-1852 PMID: 2172589 Document Number: 364997
Document emailed within 1 workday
Related Documents
Lange, G.; Wilms, K. 1988: Blood component therapy program for surgical practice. Comment on the article by Glück, Dorothee, Kubenek and Ahnefeld: blood component therapy--a transfusion plan for consequent use of volume replacement, mass transfusion and in shock Anaesthesiologie und Reanimation 13(3): 183-188Kara, I.Oguz.; Sahin, B.; Gunesacar, R.; Unsal, C. 2006: Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma Advances in Therapy 23(4): 635-645
Andresen, J.L.; Ehlers, N. 1998: Chemotaxis of human keratocytes is increased by platelet-derived growth factor-BB, epidermal growth factor, transforming growth factor-alpha, acidic fibroblast growth factor, insulin-like growth factor-I, and transforming growth factor-beta Current Eye Research 17(1): 79-87
Avent, M.; Cory, B.J.; Galpin, J.; Ballot, D.E.; Cooper, P.A.; Sherman, G.; Davies, V.A. 2002: A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country Journal of Tropical Pediatrics 48(4): 227-233
Drize, N.; Chertkov, J.; Zander, A. 1995: Hematopoietic progenitor cell mobilization into the peripheral blood of mice using a combination of recombinant rat stem cell factor (rrSCF) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) Experimental Hematology 23(11): 1180-1186
Toyama, H. 1984: Recent advances in blood transfusion - blood component therapy Nursing Technique 30(2): 160-165
Jacobs, P. 1974: Blood transfusion thoughts on component therapy Central African Journal of Medicine 20(9): 179-181
Rizzino, A.; Kazakoff, P.; Ruff, E.; Kuszynski, C.; Nebelsick, J. 1988: Regulatory effects of cell density on the binding of transforming growth factor beta, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor Cancer Research 48(15): 4266-4271
Espevik, T.; Figari, I.S.; Ranges, G.E.; Palladino, M.A. 1988: Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1 Journal of Immunology 140(7): 2312-2316
Bergmann, H. 1980: Blood component therapy: differential indication for erythrocyte transfusion Infusionstherapie und Klinische Ernahrung 7(4): 184-189
García Gala, J.M.; Rodríguez Vicente, P.; Bernal del Castillo, T.; Martínez Revuelta, E.; Corte Buelga, J.R.; Rodríguez Luengo, J.; Vargas Pabón, M. 1996: Adequacy of blood component transfusion according to previously established criteria Sangre 41(1): 19-23
Butler, A.A.; Blakesley, V.A.; Poulaki, V.; Tsokos, M.; Wood, T.L.; LeRoith, D.; Pouliki, V. 1998: Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression Cancer Research 58(14): 3021-3027
Kato, M. 1998: Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes Hokkaido Journal of Medical Science 73(6): 613-625
Buziashvili, I.I.; Matskeplishvili, S.T.; Asymbekova, E.U.; Khapiĭ, I.K.; Kamardinov, D.K.; Buval'tsev, V.I. 2003: Effect of dipyridamole on blood levels of fibroblast growth factor and vascular endothelial growth factor in patients with ischemic heart disease Kardiologiia 43(6): 14-17
Komorowski, J.; Jankewicz, J.; Stepień, H. 2000: Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours Cytobios 101(398): 151-159
Brockes, J.P. 1983: Glial growth factor--a new component of the brain and pituitary Birth Defects Original Article Series 19(4): 277-285
Skachilova, N.N.; Umnova, M.A.; Morozova, A.D.; Shakhsuvarov, V.D.; Beliaev, V.V. 1982: Blood transfusion complications due to Kell factor incompatibility of the transfused blood Problemy Gematologii i Perelivaniia Krovi 27(12): 16-20
Velleman, S.G.; McFarland, D.C. 1999: Influence of fibroblast growth factor, insulin-like growth factor I, and transforming growth factor beta on satellite cell type i collagen expression and localization during differentiation Cytobios 100(394): 101-110
Peschen, M.; Grenz, H.; Grothe, C.; Schöpf, E.; Vanscheidt, W. 1998: Patterns of epidermal growth factor receptor, basic fibroblast growth factor and transforming growth factor-beta3 expression in skin with chronic venous insufficiency European Journal of Dermatology: Ejd 8(5): 334-338
Abdullah, N.A.; Torres, B.A.; Basu, M.; Johnson, H.M. 1989: Differential effects of epidermal growth factor, transforming growth factor-alpha, and vaccinia virus growth factor in the positive regulation of IFN-gamma production Journal of Immunology 143(1): 113-117